Together with our previous study using the anti-CEA immunotoxin MFE23GRNLY [21], the present work opens the door to the use of granulysin-based immunotoxins for cancer treatment, expanding also its application to a broader spectrum of cancer types in the case of immunotoxins directed against the Tn antigen. This evidence concerns the gene GNLY and cancer.